U.S. Markets open in 8 hrs 47 mins

ShockWave Medical, Inc. (SWAV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
86.25-6.94 (-7.45%)
At close: 4:00PM EST
Sign in to post a message.
  • B
    Benpattan
    Pre/post prices are historically nutty on SWAV. Stock not actively followed, no liquidity. Made new high Friday so maybe some profit taking, but post-market volume was only 1700 shares. Early last week it was trading premarket at 93 (down from 96), then opened at 95+. Another day it was at 98 premarket and opened at 95. Concentrate on the fundamentals. That’s where it will make it big, and could well be acquired by Abiomed (or someone else). The technology is exciting and is now gaining traction.
  • J
    Joseph
    People taking profits my guess is. Still a long term hold. Might be a good window to get in.
  • T
    Tei
    • Recognized revenue of $19.6 million for the third quarter of 2020, representing a 73% increase over the third quarter of 2019
    • Submitted PMA application for FDA approval of coronary IVL
    • DISRUPT CAD III IDE study results of coronary IVL featured as a late breaking presentation at the TCT Connect conference
    • DISRUPT PAD III peripheral trial results featured as a late breaking clinical trial presentation at VIVA20 conference
    • Expanded the U.S. Field team to over 100 members
    “The successes we achieved this quarter on the clinical, financial and operational fronts speak volumes in terms of confirming the value of our proprietary IVL technology for both coronary and peripheral indications and how it uniquely addresses the challenges our customers face when treating severely calcified arteries throughout the body,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “Our team has done a remarkable job of maintaining their focus on patients and physicians as we collectively work to navigate the challenges that 2020 has put in front of us all.”
    Third Quarter 2020 Financial Results
    Revenue for the third quarter of 2020 was $19.6 million, an increase of $8.3 million, or 73%, compared to the third quarter of 2019. The growth was primarily driven by sales force expansion in the U.S. and increased penetration in both U.S. and international markets.
    Gross profit for the third quarter of 2020 was $14.3 million compared to $6.9 million for the third quarter of 2019. Gross margin for the third quarter of 2020 was 73%, as compared to 61% in the same period of last year. Contributors to gross margin improvement included continued improvement in manufacturing productivity and process efficiencies.
    Operating expenses were $27.1 million for the third quarter of 2020 compared to $20.0 million in the corresponding prior year period, representing a 36% increase, primarily driven by increases in headcount since the year ago period.
    Net loss was $12.9 million in the third quarter of 2020, as compared to $13.0 million in the corresponding period of the prior year. Net loss per share was $0.38 in the third quarter of 2020.
            
    Cash and cash equivalents totaled $215.3 million as of September 30, 2020.
  • H
    Harrydoc
    Thank you $SWAV. you continue to make money for me. With excellent technology and success in PAD and CAD therapies. Your stock will continue to soar up. I hope that you do not dilute your shares and no one buys you out for cheap. At your full potential your stock is worth at least 500$. in 2 years time. A truly breakthrough technology for Cardiologists and vascular specialists.
  • Y
    Yahoo Finance Insights
    ShockWave Medical reached an all time high at 98.04
  • Y
    Yahoo Finance Insights
    ShockWave Medical reached an all time high at 100.49
  • L
    Leslie
    $13 dollars down within few days of trading
  • S
    Skippy
    Fantastic earnings. Stock will be over $100 by year end.
  • Y
    Yahoo Finance Insights
    ShockWave Medical is down 4.93% to 93.01
  • G
    GRT
    What the prediction for price ? $200 with buy out? Any ideas
  • Y
    Yahoo Finance Insights
    ShockWave Medical is down 4.94% to 88.59
  • U
    Umesh
    Avinger Inc. (avgr) is also in PAD treament segment and they recently got approval from FDA for their latest product to treat CTO. Was wondering if their products compete with SWAV or they could complement each other. Any cardio expert could provide some info.
    Bullish
  • Y
    Yahoo Finance Insights
    ShockWave Medical is up 5.51% to 86.52
  • H
    Harrydoc
    Easy 100$ by this year end. Plus a big chance that it could be a takeover target. Abiomed had invested small amount some time ago. Plus having seen it used, it works charmingly well. Routinely used in Iliac and Femoral artery calcified disease. Now added use in heart artery is a bonus. We doctors have been waiting on such a technology for a long time. This will be a huge success.
  • N
    Neurodoc
    Today’s news on CAD III success is huge!!
    Bullish
  • L
    Luis
    This stock is a rocket. Following the last earnings release it will cross $100 very soon.
  • J
    Joe
    why is swav down after hours?
  • Y
    Yahoo Finance Insights
    ShockWave Medical reached an all time high at 92.09
  • Y
    Yahoo Finance Insights
    ShockWave Medical reached an all time high at 90.04
  • Y
    Yahoo Finance Insights
    ShockWave Medical reached an all time high at 87.99